| Premier Walk-in Medical, Inc | |
|
4025 W Caldwell Ave Suite A Visalia CA 93277-9224 | |
| (559) 625-6080 | |
| (559) 625-6024 |
| Full Name | Premier Walk-in Medical, Inc |
|---|---|
| Speciality | Family Medicine |
| Location | 4025 W Caldwell Ave, Visalia, California |
| Authorized Official Name and Position | H. James Princeton (CEO/OWNER) |
| Authorized Official Contact | 5596256080 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Premier Walk-in Medical, Inc 4025 W Caldwell Ave Suite A Visalia CA 93277-9224 Ph: (559) 625-6080 | Premier Walk-in Medical, Inc 4025 W Caldwell Ave Suite A Visalia CA 93277-9224 Ph: (559) 625-6080 |
| NPI Number | 1053338707 |
|---|---|
| Provider Enumeration Date | 07/17/2006 |
| Last Update Date | 05/18/2015 |
| Medicare PECOS PAC ID | 8820035652 |
|---|---|
| Medicare Enrollment ID | O20050413000910 |
News Archive
The U.S FDA have pushed back the deadline for deciding whether to approve an experimental anticlotting drug developed jointly by Pfizer Inc. and Bristol-Myers Squibb Co. The companies said late Wednesday that the Food and Drug Administration has set a new target date of June 28 for deciding whether to approve Eliquis. That's three months later than originally scheduled.
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from Yale Cancer Center and the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine.
Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases.
Governments could substantially reduce the tragic death toll of infants and mothers by making postnatal care services more accessible – especially to impoverished and poorly educated women in rural areas, according to a study published in the Bulletin of the World Health Organization today.
› Verified 5 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1053338707 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | A40100 (California) | Primary |
| Provider Name | Harvard J Princeton |
|---|---|
| Provider Type | Practitioner - Family Practice |
| Provider Identifiers | NPI Number: 1033117775 PECOS PAC ID: 7719924547 Enrollment ID: I20050413000987 |
News Archive
The U.S FDA have pushed back the deadline for deciding whether to approve an experimental anticlotting drug developed jointly by Pfizer Inc. and Bristol-Myers Squibb Co. The companies said late Wednesday that the Food and Drug Administration has set a new target date of June 28 for deciding whether to approve Eliquis. That's three months later than originally scheduled.
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from Yale Cancer Center and the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine.
Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases.
Governments could substantially reduce the tragic death toll of infants and mothers by making postnatal care services more accessible – especially to impoverished and poorly educated women in rural areas, according to a study published in the Bulletin of the World Health Organization today.
› Verified 5 days ago
| Provider Name | Charles R Newton |
|---|---|
| Provider Type | Practitioner - Internal Medicine |
| Provider Identifiers | NPI Number: 1285836197 PECOS PAC ID: 2365584307 Enrollment ID: I20100128000659 |
News Archive
The U.S FDA have pushed back the deadline for deciding whether to approve an experimental anticlotting drug developed jointly by Pfizer Inc. and Bristol-Myers Squibb Co. The companies said late Wednesday that the Food and Drug Administration has set a new target date of June 28 for deciding whether to approve Eliquis. That's three months later than originally scheduled.
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from Yale Cancer Center and the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine.
Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases.
Governments could substantially reduce the tragic death toll of infants and mothers by making postnatal care services more accessible – especially to impoverished and poorly educated women in rural areas, according to a study published in the Bulletin of the World Health Organization today.
› Verified 5 days ago
News Archive
The U.S FDA have pushed back the deadline for deciding whether to approve an experimental anticlotting drug developed jointly by Pfizer Inc. and Bristol-Myers Squibb Co. The companies said late Wednesday that the Food and Drug Administration has set a new target date of June 28 for deciding whether to approve Eliquis. That's three months later than originally scheduled.
People who received complementary therapy for curable cancers were more likely to refuse at least one component of their conventional cancer treatment, and were more likely to die as a result, according to researchers from Yale Cancer Center and the Cancer Outcomes, Public Policy and Effectiveness Research Center at Yale School of Medicine.
Scientists at A*STAR's Institute of Medical Biology (IMB) and Institute of Molecular and Cellular Biology (IMCB) have identified a gene encoding a hormone that could potentially be used as a therapeutic molecule to treat heart diseases.
Governments could substantially reduce the tragic death toll of infants and mothers by making postnatal care services more accessible – especially to impoverished and poorly educated women in rural areas, according to a study published in the Bulletin of the World Health Organization today.
› Verified 5 days ago
Wei Tzuoh Chen Md Facp A Professional Corp Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 431 S Bridge Street, Visalia, CA 93277 Phone: 559-732-4662 Fax: 559-636-2733 | |
Compassionate Family Care Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 306 N Conyer St, Visalia, CA 93291 Phone: 559-713-1101 Fax: 559-713-1121 | |
Oakview Medical Group Primary Care Clinic Medicare: Medicare Enrolled Practice Location: 1011 N. Demaree St., Visalia, CA 93291 Phone: 559-734-6700 Fax: 559-734-6705 | |
San Joaquin Prime Care Medical Group Inc. Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 536 N Court St, Visalia, CA 93291 Phone: 559-592-2134 | |
Premier Walk-in Medical Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 4025 W Caldwell Ave, Suite A, Visalia, CA 93277 Phone: 559-733-4505 Fax: 559-733-0876 | |
County Of Tulare Health And Human Services Agency Primary Care Clinic Medicare: Not Enrolled in Medicare Practice Location: 2505 N. Dinuba Blvd., Visalia, CA 93291 Phone: 559-624-8000 |